-+ 0.00%
-+ 0.00%
-+ 0.00%

Pyxis Oncology to Present MICVO Phase 1 Data in Head and Neck Cancer

PUBT·10/27/2026 12:45:33
Listen to the news
Pyxis Oncology to Present MICVO Phase 1 Data in Head and Neck Cancer
  • Pyxis Oncology will present Phase 1 micvotabart pelidotin monotherapy data Nov. 19, 2026, at the EORTC-NCI-AACR symposium in Barcelona.
  • The study involves previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma.
  • Two preclinical posters are scheduled for Nov. 18, including findings showing longer responses with micvotabart pelidotin combined with EGFR-targeted therapy in models.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270845PRIMZONEFULLFEED9853918) on October 27, 2026, and is solely responsible for the information contained therein.